When it comes to biotech in 2021, the author of today’s article expects the sector to remain very attractive, noting that “Valuations are quite reasonable and earnings have steadily increased. […]
read moreThe Leaders And Losers Of The S&P’s March Higher
The S&P 500 could soon hit a new high – and keep on going from there, according to company analysts who see the benchmark gaining 7% over the next year. […]
read more